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Summary The presence of high-affinity 67-kDa laminin receptors, detected immunohistochemically, was determined on 63 primary breast
cancers and on metachronous metastatic lesions or contralateral cancers from the same patients. A disagreement was observed in two-thirds
of the cases. In particular, laminin receptor content was significantly lower (P = 0.02) in local recurrences and slightly higher in lymph node
metastasis than in the corresponding primary tumours.
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Metastasis is the primary cause of fatal outcome for patients with
malignant disease. Metastatic spread includes a cascade of events
from tumour cell invasion in the adjacent stroma, migration
through the extracellular matrix and invasion into the walls of
blood or lymph vessels to colony formation in the secondary sites
(Liotta, 1986). Only cells able to adhere to the extracellular matrix
component can succeed in metastasis (Liotta, 1986). Interaction
between cancer cells and laminin, viaexpression oflaminin recep-
tors (LRs) and/or laminin-binding proteins, plays a critical role
during tumour metastasis because laminin is a major component
of the basement membrane (Hunt, 1989; Castronovo, 1993).
Available information on a large number of laminin-binding
proteins with biologically active domains demonstrates the
complexity ofcellular interactions with laminin.
The identification of several new laminin-binding proteins and
the availability of reagents able to detect different LRs belonging
to the same gene family have raised the difficult task ofattributing
specific biological functions, not necessarily involved in invasion
and metastasis, to specific receptors and of investigating their
clinical role.
Several studies on different tumour types have reported that an
increased expression ofLR results in a more aggressive phenotype
(Cioce et al, 1991; D'Errico et al, 1991; Martignone et al, 1993).
However, in breast cancer, such afinding has not been consistently
reported (Marques et al, 1990; Daidone et al, 1991), and such
contrasting results could be due to the different reagents employed
as well as to differences among case series or the clinical end
points considered. In particular, in a previous study on a substan-
tial series of patients with node-negative cancers, a high expres-
sion ofLR was associated with a high frequency oflocal-regional
recurrences but not with other unfavourable events (Daidone et al,
1991). Such a finding could support the hypothesis that activation
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ofthe laminin-LR pathway is one ofthe major factors responsible
for local invasion.
In the present study, we determined the expression of LR in
primary and metachronous lesions from individual patients also in
relation to metastatic site.
PATIENTS AND METHODS
Tumour material and patient population
LR expression of the primary breast cancer and of its metachro-
nous metastasis was assessed by immunohistochemistry on
tumour specimens from 63 patients admitted to the Istituto
Nazionale Tumori of Milan during the period September 1978 to
April 1989. Determinations on primary tumours were performed
at diagnosis before any treatment. The metastatic lesions under-
wentbiopsy forpathological assessment andbiological determina-
tions at the time of relapse, which ranged from 6 to 107 months
(median 24 months). The metachronous lesions studied were: 24
local recurrences, 17 lymph nodes, five visceral metastases and 17
contralateral cancers. Chemotherapy, hormone therapy or both
were given between surgery ofthe primary tumour and appearance
of the metastatic lesion in 38 patients, and 25 patients did not
receive any type ofsystemic treatment.
Determination of LR
Immediately after surgery or biopsy, tumour material underwent
the conventional histological procedure. The presence of LR was
evaluated by the immunohistochemical technique previously
described (Daidone et al, 1991). From each paraffin-embedded
block, 5-gm sections were processed with an anti-LR synthetic
peptide-antibody 3801 as previously described (Wewer et al,
1986) using the peroxidase-antiperoxidase method (Steinberger
1979). Negative control slides were treated with preimmune rabbit
immunoglobulins instead of specific antibody. Anti-LR antibody
stained the cell surface and the cytoplasm. The presence ofLR was
estimated by two independent observers and was expressed as the
percentage of labelled cells over the total number of tumour cells
(at least 1000 cells per specimen).
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Table 1 Agreementa in percentage of LR-positive cells in two lesions from
the same patient
Primary cancer, Metachronous lesions: LR-positive cells (%)
LR-positive cells (%)
< 30 30-60 > 60
< 30 3 16 6
30-60 11 16 11
> 60 14 10 13
aPercentage of cases.
Table 2 Agreement in LR expression between primary and metachronous
lesions or contralateral cancers
Site of unfavourable Primary vs metachronous lesions (%)
events
Equal Higher Lower
Local recurrence 25 50 25
Lymph nodal relapse 29 18 53
Contralateral cancer 30 35 35
RESULTS AND DISCUSSION
The median number ofLR-expressing cells in the primary tumours
was similar to that detected in the metachronous metastatic lesions
(50%; range 0.0-90%). Within primary tumours, LR expression
was high in those destined to develop local recurrence (median
value 65% ofpositive cells), whereas within metachronous lesions
LR expression was high in lymph nodal relapses (median value
60% of positive cells). When primary and metastatic lesions were
matched, a very low correlation was observed between the
percentage of LR-positive cells of primary and metastatic lesions
from individual patients. This finding was consistent for the
overall series (rs = -0.15) and for subsets of patients with similar
types of metachronous lesions.
In a further qualitative analysis, tumours were classified into
three subgroups with low (less than 30% positive cells), interme-
diate (30-60%) or high (more than 60%) LR content. Overall
(Table 1), an agreement in LR profile between the primary and its
metachronous lesion or contralateral cancer was observed in only
32% of the cases. In 68% of the cases, in which a disagreement
was detected, a higher or lower LR content in primary cancers than
in metachronous lesions or contralateral tumours was equally
observed. This finding confirmed the marked interlesional hetero-
geneity observed even for other functional markers, such as cell
proliferation rate (Silvestrini, 1992).
Quantitative and qualitative analyses performed on the
subgroup ofpatients with the most frequently observed metachro-
nous metastases (local or lymph node) and contralateral tumours
showed a significantly higher LR content in the primary than in
local recurrences (Wilcoxon's rank-sum test for paired samples,
P = 0.02) and a slightly lower LR in the primary than in lymph
node metastasis (P = 0.10). An equal, lower or higher LR content
in the primary than in contralateral tumours was indifferently
observed (Table 2).
It remains to be defined whether the independent pattern of LR
expression in primary and metachronous lesions can be ascribed to
different selective pressures or is simply due to the biological
interlesional heterogeneity of breast cancer specimens. However,
such findings further support the role of LR as a feature of the
primary tumour, putatively involved in the control of local inva-
sion. Whether such a biological function is specific for the LR
detected by the antibody 3801 or is shared by the other high-
affinity LRs remains to be investigated. The expression pattern of
the integrin receptors that bind laminin should be elucidated in the
same clinical model of primary and metastatic lesions to investi-
gate their actual participation in breast cancer invasion and meta-
stasis. Only such comparative analyses on the same case series
will clarify the clinical role of the different laminin-binding
proteins and explain the contrasting results on breast cancer
progression (Natali, 1992).
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